Optimizing Ovarian Cancer Treatment and Prevention Through Parallel Germline and Somatic Genetic Testing

Author:
Janice S. Kwon Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada

Search for other papers by Janice S. Kwon in
Current site
Google Scholar
PubMed
Close
 MD
Restricted access

Disclosures: Dr. Kwon has disclosed receiving grant/research support from Michael Smith Health Research BC, and is a shareholder of Hexamer Therapeutics.

Correspondence: Janice S. Kwon, MD, University of British Columbia, Department of Obstetrics and Gynecology, 2775 Laurel Street, 6th Floor, Vancouver, BC, Canada. Email: Janice.Kwon@vch.ca

View associated content

  • Collapse
  • Expand
  • 1.

    World Ovarian Cancer Coalition. Global ovarian cancer charter data briefing. Accessed January 1, 2024. Available at: https://worldovariancancercoalition.org/wp-content/uploads/2022/02/Global-Priority_Final.pdf

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2021;397:21822193.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Cabasag CJ, Butler J, Arnold M, et al. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): a population-based study. Gynecol Oncol 2020;157:234244.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Norquist BM, Harrell MI, Brady MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2:482490.

  • 5.

    Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017;317:24022416.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol 2023;41:609617.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Møller P, Hagen AI, Apold J, et al. Genetic epidemiology of BRCA mutations—family history detects less than 50% of the mutation carriers. Eur J Cancer 2007;43:17131717.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Manchanda R, Sun L, Sobocan M, et al. Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. J Natl Compr Canc Netw 2024;22:e237331.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796797.

  • 10.

    Kwon JS, Tinker AV, Santos J, et al. Germline testing and somatic tumor testing for BRCA1/2 pathogenic variants in ovarian cancer: what is the optimal sequence of testing? JCO Precis Oncol 2022;6:e2200033.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Schrag D, Kuntz KM, Garber JE, et al. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:14651471.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Hanley GE, Pearce CL, Talhouk A, et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw Open 2022;5:e2147343.

  • 13.

    Kaur P, Rufin K, Finlayson SJ, et al. Opportunistic salpingectomy between 2017 and 2020: a descriptive analysis. J Obstet Gynaecol Can 2024;46:102278.

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1271 1271 568
PDF Downloads 820 820 378
EPUB Downloads 0 0 0